Assessment of Serum Lipoprotein-Associated Phospholipase A2 in Statin  Treated Hypertensive Patients with Cardiovascular Risk

Jawad Ahmad Khan, Muhammad Ahmad Raza Butt, Muhammad Anwar Bangulzai, Zarrar Arif, Syed Azhar Hussain Zaidi, Nimra Ijaz

Assessment of Serum Lipoprotein-Associated Phospholipase A2 in Statin Treated Hypertensive Patients with Cardiovascular Risk

Authors

Jawad Ahmad Khan, Muhammad Ahmad Raza Butt, Muhammad Anwar Bangulzai, Zarrar Arif, Syed Azhar Hussain Zaidi, Nimra Ijaz

Keywords:

Statin‐treated hypertensive patients remain at risk for cardiovascular events despite achievement of lipid-lowering goals. Lipoprotein-associated phospholipase A₂ (Lp-PLA₂), an enzyme linked to vascular inflammation and plaque instability, may serve as an independent biomarker in this

Abstract

Statin‐treated hypertensive patients remain at risk for cardiovascular events despite achievementof lipid-lowering goals. Lipoprotein-associated phospholipase A₂ (Lp-PLA₂), an enzyme linked tovascular inflammation and plaque instability, may serve as an independent biomarker in this

References

Kablak-Ziembicka A, Przewlocki T. Clinical significance of carotid intima-media complex... J Clin Med. 2021;10(20):4628.

Smith J, et al. Lipoprotein-associated phospholipase A2 and carotid plaque instability. Atherosclerosis. 2021;318:1-8.

Downloads

Published

2025-07-28

How to Cite

Jawad Ahmad Khan, Muhammad Ahmad Raza Butt, Muhammad Anwar Bangulzai, Zarrar Arif, Syed Azhar Hussain Zaidi, Nimra Ijaz. (2025). Assessment of Serum Lipoprotein-Associated Phospholipase A2 in Statin Treated Hypertensive Patients with Cardiovascular Risk . International Journal of Pharmacy Research & Technology (IJPRT), 15(2), 822–828. Retrieved from https://ijprt.org/index.php/pub/article/view/785